Physicochemical characterization of SiRNA-peptide complexes

Biotechnology Progress

Volumn 24, Issue 4, 2008, Pages 957-963

  Law, Maggie ^a   Jafari, Mousa ^a   Chen, P ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Complexation; Equilibrium; Noncovalent interaction; Peptide; SiRNA silencing; Spectroscopy

Indexed keywords

ABSORPTION; AMINES; AMINO ACIDS; CHEMICAL BONDS; CHEMOTHERAPY; CIRCULAR DICHROISM SPECTROSCOPY; CIVIL AVIATION; CONCENTRATION (PROCESS); DICHROISM; DYNAMIC LIGHT SCATTERING; DYNAMIC LOADS; ELECTROPHORETIC MOBILITY; FLUID DYNAMICS; FLUID MECHANICS; HYDRODYNAMICS; LIGHT SCATTERING; MUSCULOSKELETAL SYSTEM; NUCLEIC ACIDS; OPTICAL PROPERTIES; PHOTODEGRADATION; REFRACTION; RNA; SULFATE MINERALS; SURFACE CHARGE; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL;

BINDING RATIO; BREAST CANCERS; CELL-PENETRATING PEPTIDE; CELLULAR UPTAKE; CIRCULAR DICHROISM; COMPLEXATION; CONNECTIVE TISSUE GROWTH FACTOR; ENZYMATIC DEGRADATION; EQUILIBRIUM; HIV-1 TAT; HYDRODYNAMIC DIAMETERS; MOLECULAR ASSOCIATIONS; NONCOVALENT INTERACTION; PEPTIDE; PEPTIDE COMPLEXES; PEPTIDE CONCENTRATION; PHYSICO-CHEMICAL CHARACTERIZATION; RNA INTERFERENCE; SALT ADDITION; SHORT INTERFERING; SIGNAL CONTRIBUTION; SIRNA SILENCING; SOLUTION STABILITY; SPECTROSCOPY; TRANSFECTION EFFICIENCY; UV/VIS SPECTRA; UV/VIS SPECTROSCOPY; ZETA POTENTIALS;

CHLORINE COMPOUNDS;

CONNECTIVE TISSUE GROWTH FACTOR; DRUG CARRIER; PEPTIDE; SMALL INTERFERING RNA;

CHEMISTRY; CIRCULAR DICHROISM; CONFERENCE PAPER; EVALUATION; GENETICS; HUMAN; METHODOLOGY;

CHEMISTRY, PHARMACEUTICAL; CIRCULAR DICHROISM; CONNECTIVE TISSUE GROWTH FACTOR; DRUG CARRIERS; HUMANS; PEPTIDES; RNA, SMALL INTERFERING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 51849101139     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1002/btpr.13     Document Type: Conference Paper

References (26)

1. Agrawal S, Iyer RP. Perspectives in Antisense Therapeutics. Pharmacol. & Ther. 1997;76:151-60.
2. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
3. Novina CD, Sharp PA. The RNAi revolution. Nature 2004;430:161.
4. Paddison P, Caudy A, Bernstein E, Hannon G, Conklin D. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16:948.
5. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes. Cell 2005;123:607-20.
6. Rand TA, Petersen S, Du F, Wang X. Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation. Cell 2005;123:621-29.
7. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs Exhibit Strand Bias. Cell 2003;115:209-16.
8. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomater. 2006;27:4356-73.
9. Mahato RI. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids, CRC Press: Boca Raton, FL; 2005.
10. Owens DE, III; Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J Pharm 2006;307:93-102.
11. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7:657-63.
12. Eliyahu H, Siani S, Azzam T, Domb AJ, Barenholz Y. Relationships between chemical composition, physical properties and transfection efficiency of polysaccharide-spermine conjugates. Biomater. 2006;27:1646-55.
13. Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC, Sung HW. Paclitaxel-loaded poly(γ-glutamic acid)-poly (lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomater. 2006; 27:2051-59.
14. Hashida M, Akamatsu K, Nishikawa M, Yamashita F, Takakura Y. Design of polymeric prodrugs of prostaglandin E1 having galactose residue for hepatocyte targeting. J Controlled Release 1999;62:253-62.
15. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92.
16. D'Souza AJM, Topp EM. Release from polymeric prodrugs: linkages and their degradation. J Pharm Sci. 2004;93:1962-79.
17. Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit D, Yang H. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol. 2005;2:8.
18. Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst. 1987;3:233-61.
19. Lejeune D, Delsaux N, Charloteaux B, Thomas A, Brasseur R. Protein-nucleic acid recognition: Statistical analysis of atomic interactions and influence of DNA structure. Proteins 2005;61:258-71.
20. Jones SDDTA, Luscombe NM, Berman HM, Thornton JM. Protein-RNA interactions: a structural analysis. Nucleic Acids Res. 2001;29:943-54.
21. Bloomfield VA, Crothers DM, Tinoco I. Nucleic acids: structures, properties, and functions, University Science Books: Sausalito, CA; 2000.
22. Bujalowski W, Lohman TM. A general method of analysis of ligand-macromolecule equilibria using a spectroscopic signal from the ligand to monitor binding. Application to Escherichia coli single-strand binding protein-nucleic acid interactions. Biochem. 1987;26:3099-106.
23. Wang M, Law M, Duhamel J, Chen P. Interaction of a Self-Assembling Peptide with Oligonucleotides: Complexation and Aggregation. Biophysical Journal 2007;93:2477-90.
24. Wagner KG. On the Interaction of Nucleotides with Basic Polyamino Acids. Cooperative Binding Behavior. Eur J Biochem. 1969;10:261.
25. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell JE. Molecular Cell Biology, WH. Freeman & Co.: New York; 1999.
26. Hunter RJ. Zeta potential in colloid science: principles and applications, Academic Press: London; 1981.